Table 3.
Treatment-related adverse events of trastuzumab deruxtecan (all grade, grade 3/4 or grade 5)
| TRAE | All grade (%) | Grade 3/4 (%) | Grade 5 (%) | |
|---|---|---|---|---|
| Hematologic | Decreased neutrophil count | 34.8 | 20.7 | 0 |
| Anemia | 29.9 | 8.7 | 0 | |
| Decreased white cell count | 21.2 | 6.5 | 0 | |
| Decreased platelet count | 21.2 | 4.3 | 0 | |
| Decreased lymphocyte count | 14.1 | 6.5 | 0 | |
| Gastrointestinal | Diarrhea | 29.3 | 2.7 | 0 |
| Constipation | 35.9 | 0.5 | 0 | |
| Nausea | 77.7 | 7.6 | 0 | |
| Vomiting | 45.7 | 4.3 | 0 | |
| Decreased appetite | 31.0 | 1.6 | 0 | |
| Abdominal pain | 16.8 | 1.1 | 0 | |
| Lung | Interstitial lung disease | 15.2 | 0.5 | 2.7 |
| Cough | 19 | 0 | 0 | |
| Heart | Prolonged QT interval | 4.9 | 1.1 | 0 |
| Decreased LV ejection fraction | 1.6 | 0.5 | 0 | |
| Other | Fatigue | 49.5 | 6.0 | 0 |
| Alopecia | 48.4 | 0.5 | 0 | |
| Headache | 19.6 | 0 | 0 |